Prednisolone phosphate

Prednisolone phosphate Overview

Prednisolone phosphate is a synthetic, water-soluble inorganic phosphate ester derivative of prednisolone. Chemically, it belongs to the class of organic compounds known as gluco/mineralocorticoids, progestogins and derivatives within the pregnane steroids sub-class. Structurally, it consists of a 11β,17α,21-trihydroxypregna-1,4-diene-3,20-dione steroid nucleus esterified at the C-21 position with a phosphate moiety and neutralized as a disodium salt, possessing a molecular weight of 464.4 g/mol.

What Is Prednisolone phosphate and How Does It Work?

Prednisolone phosphate acts primarily through enzymatic cleavage by tissue phosphatases to yield free active prednisolone, followed by intracellular glucocorticoid receptor agonism to induce lipocortins and suppress pro-inflammatory NF-κB transcription, driving inhibition of phospholipase A2, suppression of capillary permeability and leukocyte extravasation, and blunting of prostaglandin/leukotriene cascades.

Is Prednisolone phosphate FDA Approved?

Prednisolone phosphate (as prednisolone sodium phosphate) was approved by the US FDA on December 19, 1973. Current FDA-approved formulations include Pediapred oral solution, Orapred ODT orally disintegrating tablets, and prescription generic ophthalmic/oral solutions. Its current regulatory status is FDA Approved.

What Was/Is Prednisolone phosphate Used For?

• Systemic treatment of pediatric acute asthma exacerbations, croup (laryngotracheobronchitis), nephrotic syndrome, and acute allergic reactions (Pediapred, Orapred ODT).
• Treatment of steroid-responsive ocular inflammatory conditions including anterior uveitis, iridocyclitis, allergic conjunctivitis, superficial punctate keratitis, herpes zoster keratitis, and post-operative ocular inflammation.
• Combination ophthalmic therapy with antibacterial agents (sulfacetamide sodium) for ocular inflammation complicated by superficial bacterial infections.

Before Taking Prednisolone phosphate: Contraindications & Precautions

Do not administer Prednisolone phosphate to patients with a known severe hypersensitivity to prednisolone, prednisolone sodium phosphate, or formulation excipients. Systemic oral administration is strictly contraindicated in patients with untreated systemic fungal infections. Topical ophthalmic administration is strictly contraindicated in patients with active viral diseases of the cornea and conjunctiva, including epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, and varicella, as local immunosuppression accelerates viral replication and corneal perforation. Ophthalmic formulations are also contraindicated in mycobacterial (ocular tuberculosis) and fungal ocular infections.

Who Should Not Take Prednisolone phosphate?

• Individuals with untreated systemic fungal infections (for systemic oral administration).
• Patients with active viral corneal/conjunctival infections (active dendritic Herpes Simplex Keratitis, vaccinia, varicella).
• Patients with active mycobacterial or fungal ocular infections.

Prednisolone phosphate, Pregnancy & Safety

Systemic oral glucocorticoids cross the human placenta and are classified as Pregnancy Category C. Epidemiological studies associate systemic corticosteroid administration during the first trimester with a small increased risk of fetal oral clefts (cleft lip/palate), intrauterine growth restriction, and decreased birth weight. Topical ophthalmic instillation results in lower systemic plasma exposure than oral dosing, but systemic absorption occurs via nasolacrimal drainage. Prednisolone phosphate should be used during pregnancy only if the potential maternal benefit clearly justifies potential fetal risks, utilizing nasolacrimal occlusion during eye drop instillation. Prednisolone is excreted in human breast milk; high-dose systemic therapy may suppress infant growth or interfere with endogenous corticosteroid production.

Tell Your Doctor Before Taking Prednisolone phosphate

Inform your physician, pediatrician, or ophthalmologist if you have a history of glaucoma, elevated intraocular pressure, cataracts, ocular herpes simplex, peptic ulcer disease, tuberculosis, diabetes, hypertension, heart failure, or recent vaccinations.

Prednisolone phosphate Dosage & Administration

Formulated as oral solutions (5 mg/5 mL, 15 mg/5 mL), orally disintegrating tablets (ODT: 10 mg, 15 mg, 30 mg), and ophthalmic solution drops (0.1%, 1.0% w/v [1 mg/mL, 10 mg/mL]).

Standard Prednisolone phosphate Dosing

• Ophthalmic Inflammatory Conditions & Uveitis (Adults & Children): Instill 1 to 2 drops of 1.0% Prednisolone sodium phosphate solution into the conjunctival sac 2 to 4 times daily. In severe acute inflammation, instillation may be initiated at 1 to 2 drops every hour during the first 24 to 48 hours, then gradually tapered as inflammation subsides.
• Systemic Pediatric Asthma Exacerbation / Croup (Oral Pediapred / Orapred ODT): Administered as 1.0 mg/kg to 2.0 mg/kg/day orally in 1 or 2 divided doses (maximum 60 mg/day) for 3 to 5 days.

How Was/Is Prednisolone phosphate Administered

• Ophthalmic Solutions Do Not Require Shaking: Unlike prednisolone acetate suspensions, Prednisolone sodium phosphate is a clear solution; no shaking is needed.
• For eye drops: Tilt head back, pull lower eyelid down, instill 1 drop into the pouch, and press the finger against the inner corner of the eye (lacrimal sac) for 1 to 2 minutes (nasolacrimal occlusion) to reduce systemic absorption.

Prednisolone phosphate Clinical Efficacy & Research

In clinical pediatrics, ophthalmology, and anti-inflammatory research, Prednisolone phosphate is established as a highly bioavailable glucocorticoid. Clinical pediatric trials evaluating oral prednisolone sodium phosphate solutions (Pediapred) and ODT formulations in children with acute asthma exacerbations demonstrate that a 3- to 5-day course achieves equivalent clinical efficacy to oral prednisone tablets, producing rapid improvement in forced expiratory volume (FEV1), lower hospitalization rates, and significantly higher compliance due to improved palatability. In clinical ophthalmology, comparative trials show that 1.0% Prednisolone sodium phosphate ophthalmic solution provides rapid corneal penetration and anti-inflammatory action in anterior segment inflammation.

Prednisolone phosphate Side Effects & Safety Profile

Prednisolone phosphate exhibits a safety profile characteristic of potent glucocorticoids. Safety hazards stem primarily from systemic exposure during prolonged oral therapy or intraocular pressure elevation during chronic ophthalmic use.

Adverse effects depend on the route, dose, and duration of therapy.

Common Prednisolone phosphate Side Effects

• Ophthalmic Application: Transient ocular stinging, burning upon instillation, mild conjunctival hyperemia, and blurred vision.
• Systemic Oral Application (Short-Term): Increased appetite, weight gain, transient mood changes (irritability, euphoria), facial flushing, gastrointestinal upset, and insomnia.

Serious Prednisolone phosphate Adverse Events

• Elevated Intraocular Pressure (IOP) & Glaucoma: Uncontrolled IOP elevation leading to optic nerve damage and visual field defects following extended ophthalmic or systemic use.
• Posterior Subcapsular Cataracts: Lens opacification secondary to prolonged corticosteroid exposure.
• Hypothalamic-Pituitary-Adrenal (HPA) Axis Suppression: Secondary adrenocortical insufficiency following abrupt cessation of chronic systemic therapy.
• Immunosuppression & Infection Reactivation: Increased susceptibility to bacterial, fungal, or viral infections; reactivation of latent ocular herpes simplex or tuberculosis.

Managing Prednisolone phosphate Side Effects

Monitor intraocular pressure after 10 days of ophthalmic therapy. If systemic therapy exceeds 14 days, taper the dose gradually rather than stopping abruptly to prevent adrenal crisis. Administer oral doses with food to minimize stomach upset.

Prednisolone phosphate Drug Interactions & What to Avoid

Prednisolone phosphate undergoes hepatic metabolism via CYP3A4 enzymes and exhibits important pharmacodynamic interactions.

Co-administration with specific drug classes alters systemic clearance or efficacy.

Prednisolone phosphate Drug-Drug Interactions

• CYP3A4 Inducers (Rifampin, Phenytoin, Carbamazepine, Phenobarbital): Accelerate hepatic metabolism of prednisolone, lowering plasma concentrations and therapeutic efficacy; increase prednisolone dosage if needed.
• CYP3A4 Inhibitors (Ketoconazole, Itraconazole, Clarithromycin): Inhibit prednisolone clearance, elevating plasma exposure and increasing corticosteroid side effect risks.
• Non-Steroidal Anti-Inflammatory Drugs (NSAIDs – Aspirin, Ibuprofen): Concomitant systemic oral use increases the risk of severe gastrointestinal ulceration and GI bleeding.
• Antidiabetic Agents (Insulin, Metformin, Glipizide): Glucocorticoids elevate blood glucose; dosage adjustment of antidiabetic medications may be required.

Prednisolone phosphate, Food & Alcohol

Take oral solutions or ODT tablets with food or milk to decrease gastrointestinal irritation. Avoid heavy alcohol consumption, which increases gastric mucosal ulceration risks.

Prednisolone phosphate: Missed Dose, Overdose & Storage

Proper handling of Prednisolone phosphate involves consistent daily dosing and proper storage. Overdose varies by route of administration.

Missed Dose of Prednisolone phosphate

Instill the missed eye drop or take the missed oral dose as soon as remembered. If near the time for the next scheduled dose, skip the missed dose; do not double doses.

Prednisolone phosphate Overdose & Emergency

Acute, single-dose systemic oral or ophthalmic overdose is non-life-threatening. Chronic systemic overdose results in Cushingoid features (moon face, buffalo hump, hypertension, hyperglycemia, muscle wasting). Emergency management for acute massive ingestion includes supportive fluid hydration, monitoring blood glucose and electrolytes, and symptomatic care.

How to Store Prednisolone phosphate

Store oral solutions, ODT tablets, and ophthalmic solutions at controlled room temperature between 20°C and 25°C (68°F to 77°F). Protect strictly from freezing and direct light exposure. Do not refrigerate Pediapred oral solution unless instructed by specific generic labeling. Keep containers tightly closed. Keep out of reach of children.

Prednisolone phosphate Patient Management & Monitoring

Clinical oversight for patients taking Prednisolone phosphate focuses on evaluating inflammatory control, monitoring intraocular pressure, and screening for systemic glucocorticoid side effects.

Tests Before Starting Prednisolone phosphate

Baseline intraocular pressure (IOP) check prior to extended ophthalmic therapy; baseline slit-lamp examination to rule out dendritic herpes keratitis; baseline blood pressure and fasting blood glucose for systemic therapy; baseline growth parameters (height, weight) in pediatric patients.

Monitoring During Prednisolone phosphate Treatment

Checking IOP after 10 days of continuous ophthalmic use and every 2 to 4 weeks thereafter; inspecting anterior chamber for inflammatory cell and flare reduction; monitoring blood glucose and blood pressure in high-dose systemic therapy; assessing pediatric growth curves during extended systemic courses.

Prednisolone phosphate Do’s and Don’ts

• Do perform nasolacrimal occlusion (press the inner corner of your eye) for 1 to 2 minutes after applying eye drops to minimize systemic side effects.
• Do take oral solutions or disintegrating tablets with food to prevent stomach upset.
• Do taper your oral dose gradually if instructed by your doctor after long-term use.
• Do not shake Prednisolone phosphate eye drop bottles unlike acetate suspensions, phosphate drops are clear solutions.
• Do not use Prednisolone phosphate eye drops if you have an active “cold sore” infection of the eye or dendritic herpes keratitis.
• Do not stop taking oral prednisolone abruptly if you have been on it for more than 2 weeks.

Frequently Asked Questions

References

• DrugBank Database – Prednisolone Phosphate Clinical Profile (DB14631)
• Classyfire Database – Pregnane Steroids / Steroids and Derivatives Taxonomy Profile

Legal Disclaimer

The detailed medical and chemical information provided on this specific web page is intended strictly for educational and informational purposes regarding complex pharmacological mechanisms. It absolutely does not constitute professional medical advice, medical diagnosis, or specific treatment recommendations. Always consult a licensed healthcare provider before making any personal decisions regarding complex medical conditions, medication adjustments, or dietary changes.